The landmark trial of Cetuximab combined with radiation therapy [45] has transformed clinical management of HNSCC; however, not every patient responds to this regimen, suggesting alternate pathways by which HNSCCs can escape EGFR inhibition [46]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.